Uremia Clinical Trial
Official title:
REST/Collaborative Study Initiative With the Aim of Providing More Objective Information on Volume Status and Guiding Physicians in the Quest for DW
Background Very recently, a test aimed at assessing dry weight (DW) in hemodialysis (HD)
patients has been developed, the "resistance stabilization test" (REST)
Aim of the study To verify if BIA-based DW (BIA DW) control is truly superior to current
volume management in HD patients.
Protocol of the study DW determined with clinical methods (Clinical DW) is the gold standard
by definition: Clinical DW is determined under strict clinical surveillance by the same
attending physician. He will be helped by a clinical score of volume state about symptoms
and signs of hypo- or hypervolemia. The physician is asked to adjust the DW of the
candidates until their clinical score reaches zero before the BIA measurement. This Clinical
DW will be compared with BIA DW, as obtained after performing REST
Phases of the study
The protocol study includes three sequential phases:
1. the Clinical DW is the gold standard by definition. Items of form B must be strictly
applied until score = 0 is achieved;
2. The Clinical DW as indicated by the score = 0 becomes the target DW of the next
standard HD session, in which BIA measurements are performed: R values are recorded
continuously during the session.
3. REST is performed the following dialysis session. As per protocol, these dialysis
sessions may be one or more than one, until flattening of the curve of the ratio R0/Rt
(R0 is R at time 0 and Rt is R at a given time t during the HD session) of less than +
1% over 20 minutes in the presence of ongoing UF, is obtained.
Primary outcome
The primary outcome is the definition for each patient of the gold standard DW when
comparing the Clinical and the BIA DW. Two are the possible scenarios:
1. the Clinical and the BIA DW will be very similar ( < + 0.5 kg). Therefore, a reciprocal
validation of the two methods for that specific patient has been obtained;
2. the Clinical and the BIA DW are different ( > + 0.5 kg). If the BIA DW will be
confirmed in the following six dialysis sessions, it means that the gold standard DW
for that patient is the BIA DW.
Background Probing the dry weight (DW) was largely dependent on clinical subjective
estimates until recently. New bedside non-invasive tools have been developed with the aim of
providing more objective information on volume status and guiding physicians in the quest
for DW. Among them, bioimpedance (BIA) appears to be very promising in the achievement of
this goal. Resistance (R) and capacitance of tissues are the two basic properties in BIA.
However, although impedance is an electrical property of tissues that can be directly used
in body composition analysis, it is commonly embedded in predictive equations that are
derived by correlation with criterion measures of body compartments.
Very recently, a test aimed at assessing DW in hemodialysis (HD) patients has been
developed, the "resistance stabilization test" (REST). It is based on the following four
items:
1. one or more daily and/or alternate day HD sessions lasting 6 hours with ultrafiltration
(UF) rate ≤ 0.5 kg/hour are planned;
2. BIA measurements are determined injecting 800 microAmpere at 50 kilohertz alternating
sinusoidal current with a standard tetrapolar technique (BIA 101 Impedance Analyzer).
Resistance (R) is recorded starting at the beginning of the HD session (R0) and then,
continuously, until the end of the 6-hour session;
3. DW is defined as the weight achieved after flattening of the curve of the ratio R0/Rt
(R0 is R at time 0 and Rt is R at a given time t during the HD session) of less than +
1% over 20 minutes in the presence of ongoing UF, indicating no further decline in
extracellular volume;
4. if at the end of the 6-hour HD session R stabilization is not attained, a new 6-hour HD
treatment with UF rate ≤ 0.5 kg/h is planned until a BIA DW (according to the item 3)
is obtained.
Aim of the study A study group is being created (REST/Collaborative Study Initiative) with
the aim of verifying if BIA-based DW (BIA DW) control is truly superior to current volume
management in HD patients.
Protocol of the study DW determined with clinical methods (Clinical DW) is the gold standard
by definition: Clinical DW is determined under strict clinical surveillance by the same
attending physician. He will be helped by a clinical score of volume state about symptoms
and signs of hypo- or hypervolemia. The physician is asked to adjust the DW of the
candidates until their clinical score reaches zero after a given number of HD sessions
before the BIA measurement. This Clinical DW will be compared with BIA DW, as obtained after
performing REST;
Phases of the study
The protocol study includes three sequential phases:
1. as already mentioned, the Clinical DW is the gold standard by definition. Items of form
B must be strictly applied. Form B must be filled in session after session, until score
= 0, index of euvolemia, is achieved;
2. The Clinical DW as indicated by the score = 0 becomes the target DW of the next
standard HD session, in which BIA measurements are performed: R values are recorded
continuously during the session (Form C must be filled in).
3. REST is performed the following dialysis session (all the details have been given in
the background section). As per protocol, these dialysis sessions may be one or more
than one, until flattening of the curve of the ratio R0/Rt (R0 is R at time 0 and Rt is
R at a given time t during the HD session) of less than + 1% over 20 minutes in the
presence of ongoing UF, is obtained.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
Completed |
NCT01583309 -
Effects of Convective Therapies in Dialysis Patients
|
Phase 3 | |
Completed |
NCT03437538 -
Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter
|
N/A | |
Completed |
NCT00649298 -
A Clinical Trial of IntensiVE Dialysis
|
Phase 4 | |
Completed |
NCT05750875 -
Gabapentin Versus Loratadine in Uremic Pruritus
|
Phase 4 | |
Recruiting |
NCT01408797 -
Clonal Deletion on Living-Relative Donor Kidney Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01267760 -
Clinical and Biochemical Effects of Multipass Hemodialysis
|
Phase 2 | |
Recruiting |
NCT00375635 -
Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis
|
N/A | |
Recruiting |
NCT05076318 -
Dysregulated Urea-synthesis at Terminal Uremia
|
N/A | |
Completed |
NCT05899283 -
A Comparative Study of Two Kinds of Hemodialysis Filters
|
N/A | |
Completed |
NCT04768309 -
Impact of Intestinal Microbiota on Uremic Toxins Productions
|
N/A | |
Not yet recruiting |
NCT05386433 -
Paxlovid in the Treatment of COVID-19 Patients With Uremia
|
Early Phase 1 | |
Completed |
NCT01391884 -
Elimination of Incretin Hormones in Patients With Severe Kidney Failure
|
N/A | |
Completed |
NCT00442819 -
Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney
|
Phase 4 | |
Not yet recruiting |
NCT02266238 -
Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial
|
N/A | |
Recruiting |
NCT01766895 -
Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan
|
||
Completed |
NCT00388648 -
Very Low Protein Diet or Dialysis in Uremic Elderly?
|
Phase 4 | |
Withdrawn |
NCT03416192 -
12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.
|
N/A | |
Recruiting |
NCT02606955 -
Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test
|
N/A | |
Completed |
NCT02050139 -
L-Cysteine in Peritoneal Dialysis
|
Phase 2 |